PARP1
化学
DNA修复
柔红霉素
聚ADP核糖聚合酶
细胞生物学
先天免疫系统
生物化学
聚合酶
DNA
生物
白血病
遗传学
受体
作者
Shujing Lin,Guihui Tu,Zelei Yu,Qingna Jiang,Lingyu Zhang,Haibo Liu,Quanyu Liu,Xiuwang Huang,Jianhua Xu,Yao Lin,Yang Liu,Lixian Wu
标识
DOI:10.1016/j.bmc.2022.116912
摘要
Poly ADP-ribose polymerase 1 (PARP1) plays an essential role in DNA repair signaling, rendering it an attractive target for cancer treatment. Despite the success of PARP1 inhibitors (PARPis), only a few patients can currently benefit from PARPis. Moreover, drug resistance to PARPis occurs during clinical treatment. Natural and acquired resistance to PARPis has forced us to seek new therapeutic approaches that target PARP1. Here, we synthesized a series of compounds by proteolysis-targeting chimera (PROTAC) technology to directly degrade the PARP1 protein. We found that CN0 (compound 3) with no polyethylene glycol (PEG) linker can degrade the PARP1 protein through the proteasome pathway. More importantly, CN0 could inhibit DNA damage repair, resulting in highly efficient accumulation of cytosolic DNA fragments due to unresolved unrepaired DNA lesions when combined with daunorubicin (DNR). Therefore, CN0 can activate the cyclic GMP-AMP synthase/stimulator of the interferon gene (cGAS/STING) pathway of innate immunity and then spread the resulting inflammatory signals, thereby reshaping the tumor microenvironment, which may eventually enhance T cell killing of tumor cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI